Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastro intestine that includes ulcerative colitis and Crohn’s disease.
Bowel management is an issue for many individuals, from birth through adulthood. Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastro intestine that includes ulcerative colitis and Crohn’s disease. This type of issues ranges from constipation to diarrhea and every consistency in between. Bowl management system is the treatment for neurogenic bowel that is designed to work in the intestine in order to remove stool from the body in an efficient and safe manner.
According to a report published by Allied Market Research, the global bowel management systems market size is projected to reach $3.5 billion with a considerable CAGR from 2019 to 2026. North America is currently holding the highest market share, owing to rise in geriatric population and increased prevalence of irritable stool syndrome in the region, especially in the U.S. The Asia-Pacific region, at the same time, is expected to grow at the fastest growth rate, attributed to surge in demand for healthcare infrastructure, rise in number of hospitals in emerging economies, rise in healthcare reforms, increase in development of R&D sector, and technological advancements in the field of healthcare.
What is the Impact of COVID-19 on Bowel Management Systems Market?
However, the outbreak of the COVID-19 pandemic led to have a negative impact on the growth of the global bowel management system market. The pandemic implemented global lockdown, which resulted to temporary closure of most of the IBD centers, especially in the initial phase. Also, the fact that patients with inflammatory bowel disease are often malnourished and immunocompromised, they were at high risk of COVID-19 infection. Proving special care of such patients became difficult during the pandemic.
Download Sample Report - https://www.alliedmarketresearch.com/request-sample/6458
Moreover, in order to maintain the social distancing norms, very less patients were visiting the hospital or IBD center to consult a gastroenterologist. The majority of hospitals around the world experienced a drop in outpatient numbers and routine follow-ups by more than 50% for many months in 2020.
Few more factors such as shortage of drug supply, high cost of therapy, and a lack of universal health insurance have affected access to medications for IBD patients during the pandemic. These factors hampered the growth of the global bowel management system market to some extent.
Nevertheless, the market has a huge scope to gather exponential growth in the post pandemic. IBD opinion leaders across the world are coming together in resource limited areas to prioritize management guidelines of IBD patients based on high quality scientific evidence. The key companies in the healthcare sector are focusing on R&D activities in order to develop innovative bowel management devices.